OncoDaily IO路 @OncoDailyIO 路 X路路 23 hours agoScore70
Body
馃К GDFather-NEO: Neoadjuvant visugromab + nivolumab yielded a locally assessed pCR of 33.3% vs 7.7% with nivolumab alone in MIBC.
Exploratory, nonrandomized phase II findings warrant randomized validation; an EFS benefit remains unproven.
https://oncodaily.com/oncolibrary/immune-oncology/gdfather-neo
#ESMO2026 #OncoDail #GDFatherNEO
20 views 路 0 likes 路 0 reposts 路 0 replies
Conference abstracts
4757ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial
Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab 卤 visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgSource: OncoDaily IO 路 x.com